journal article·2022-11-22Open access

PEGylated Gold Nanoparticles Target Age-Associated B Cells In Vivo

Sandra Hočevar, Viola Puddinu, Laetitia Haeni, Alke Petri-Fink, Julia Wagner, Montserrat Alvarez, Martin James David Clift, Carole Bourquin

ACS Nano· Volume 16· Issue 11

Abstract

Engineered gold nanoparticles (GNPs) have become a useful tool in various therapeutic and diagnostic applications. Uncertainty remains regarding the possible impact of GNPs on the immune system. In this regard, we investigated the interactions of polymer-coated GNPs with B cells and their functions in mice. Surprisingly, we observed that polymer-coated GNPs mainly interact with the recently identified subpopulation of B lymphocytes named age-associated B cells (ABCs). Importantly, we also showed that GNPs did not affect cell viability or the percentages of other B cell populations in different organs. Furthermore, GNPs did not activate B cell innate-like immune responses in any of the tested conditions, nor did they impair adaptive B cell responses in immunized mice. Together, these data provide an important contribution to the otherwise limited knowledge about GNP interference with B cell immune function, and demonstrate that GNPs represent a safe tool to target ABCs in vivo for potential clinical applications.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Neuroinflammation and Neurodegeneration Mechanisms · T-cell and B-cell Immunology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva 1211, Switzerland

BioNanomaterials, Adolphe Merkle Institute, University of Fribourg, Fribourg 1700, Switzerland

In Vitro Toxicology Group, Swansea University Medical School, Swansea, Wales SA2 8PP, U.K.

Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Faculty of Medicine, University of Geneva, Geneva 1211, Switzerland

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung · Adolphe Merkle Foundation

References (70)

Show source-provided references
1. 10.1038/s41598-018-21331-y10.1038/s41598-018-21331-y ↗
2. 10.1016/j.nano.2017.11.00910.1016/j.nano.2017.11.009 ↗
3. 10.1021/nn305700510.1021/nn3057005 ↗
4. 10.1016/j.jconrel.2018.02.00410.1016/j.jconrel.2018.02.004 ↗
5. 10.1088/0957-4484/21/19/19510110.1088/0957-4484/21/19/195101 ↗
6. 10.1016/j.immuni.2018.08.01210.1016/j.immuni.2018.08.012 ↗
7. 10.15252/embr.20184601610.15252/embr.201846016 ↗
8. 10.1515/pjvs-2015-003610.1515/pjvs-2015-0036 ↗
9. 10.1177/019262331877060810.1177/0192623318770608 ↗
10. 10.1016/j.nano.2012.02.01210.1016/j.nano.2012.02.012 ↗
11. 10.2147/IJN.S2165710.2147/IJN.S21657 ↗
12. 10.1021/la401556k10.1021/la401556k ↗
13. 10.1007/s13404-011-0015-810.1007/s13404-011-0015-8 ↗
14. 10.1021/acs.langmuir.6b0128910.1021/acs.langmuir.6b01289 ↗
15. 10.1038/s41565-018-0344-310.1038/s41565-018-0344-3 ↗
16. 10.1016/j.imbio.2015.06.00510.1016/j.imbio.2015.06.005 ↗
17. 10.1039/C0CS00018C10.1039/C0CS00018C ↗
18. 10.1172/JCI8108310.1172/JCI81083 ↗
19. 10.1182/blood-2011-01-33053010.1182/blood-2011-01-330530 ↗
20. 10.1182/blood-2011-01-33146210.1182/blood-2011-01-331462 ↗
21. 10.1146/annurev-immunol-092419-03113010.1146/annurev-immunol-092419-031130 ↗
22. 10.4049/jimmunol.150005510.4049/jimmunol.1500055 ↗
23. 10.1016/j.immuni.2018.08.01510.1016/j.immuni.2018.08.015 ↗
24. 10.1038/s41467-018-03750-710.1038/s41467-018-03750-7 ↗
25. 10.1371/journal.ppat.101029710.1371/journal.ppat.1010297 ↗
26. 10.3389/fimmu.2019.0031810.3389/fimmu.2019.00318 ↗
27. 10.1002/smll.20130288910.1002/smll.201302889 ↗
28. 10.1021/acsnano.9b0149210.1021/acsnano.9b01492 ↗
29. 10.1039/C4CS00487F10.1039/C4CS00487F ↗
30. 10.1039/c2nr33134a10.1039/c2nr33134a ↗
31. 10.1021/ac070208410.1021/ac0702084 ↗
32. 10.1080/17435390.2018.145992210.1080/17435390.2018.1459922 ↗
33. 10.1083/jcb.98.4.116310.1083/jcb.98.4.1163 ↗
34. 10.18632/oncotarget.1884410.18632/oncotarget.18844 ↗
35. 10.2139/ssrn.382516110.2139/ssrn.3825161 ↗
36. 10.1016/j.taap.2008.12.02310.1016/j.taap.2008.12.023 ↗
37. 10.1504/IJNT.2011.04143510.1504/IJNT.2011.041435 ↗
38. 10.1088/0957-4484/25/12/12510310.1088/0957-4484/25/12/125103 ↗
39. 10.1016/j.biomaterials.2018.10.03110.1016/j.biomaterials.2018.10.031 ↗
40. 10.1038/nri380210.1038/nri3802 ↗
41. 10.1182/blood-2008-02-07807110.1182/blood-2008-02-078071 ↗
42. 10.1371/journal.pone.001500710.1371/journal.pone.0015007 ↗
43. 10.1084/jem.2010006410.1084/jem.20100064 ↗
44. 10.4049/jimmunol.190040410.4049/jimmunol.1900404 ↗
45. 10.4049/jimmunol.160052210.4049/jimmunol.1600522 ↗
46. 10.1172/JCI8993110.1172/JCI89931 ↗
47. 10.4049/jimmunol.160110610.4049/jimmunol.1601106 ↗
48. 10.3389/fimmu.2021.64945810.3389/fimmu.2021.649458 ↗
49. 10.1016/j.celrep.2018.06.07410.1016/j.celrep.2018.06.074 ↗
50. 10.1126/sciimmunol.aai815310.1126/sciimmunol.aai8153 ↗
51. 10.3389/fimmu.2020.0003210.3389/fimmu.2020.00032 ↗
52. 10.4049/jimmunol.150005510.4049/jimmunol.1500055 ↗
53. 10.1002/smll.20130199810.1002/smll.201301998 ↗
54. 10.1016/j.imbio.2015.12.00310.1016/j.imbio.2015.12.003 ↗
55. 10.1038/nmat471810.1038/nmat4718 ↗
56. 10.1080/17435390.2019.159354110.1080/17435390.2019.1593541 ↗
57. 10.1172/jci.insight.9294310.1172/jci.insight.92943 ↗
58. 10.1016/j.cellimm.2017.04.01210.1016/j.cellimm.2017.04.012 ↗
59. 10.4049/jimmunol.090129710.4049/jimmunol.0901297 ↗
60. 10.4049/jimmunol.178.10.662410.4049/jimmunol.178.10.6624 ↗
61. 10.1371/journal.pone.012826910.1371/journal.pone.0128269 ↗
62. 10.1089/dna.2016.330410.1089/dna.2016.3304 ↗
63. 10.1002/art.3782810.1002/art.37828 ↗
64. 10.1073/pnas.131234811010.1073/pnas.1312348110 ↗
65. 10.4049/jimmunol.150036810.4049/jimmunol.1500368 ↗
66. 10.1186/s13075-017-1438-210.1186/s13075-017-1438-2 ↗
67. 10.1002/eji.20174712710.1002/eji.201747127 ↗
68. 10.1038/s41467-022-28086-110.1038/s41467-022-28086-1 ↗
69. 10.1039/df951110005510.1039/df9511100055 ↗
70. 10.1007/978-1-4939-1050-2_310.1007/978-1-4939-1050-2_3 ↗